FDA Ad Com backs Mallinckrodt’s terlipressin in close vote

The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 8-7 that the benefits of Mallinckrodt’s (MNK +11.1%) terlipressin outweigh the risks for the treatment of hepatorenal syndrome type 1.

https://seekingalpha.com/news/3591572-fda-ad-com-backs-mallinckrodts-terlipressin-in-close-vote